Cost-effectiveness of adding ezetimibe and/or PCSK9 inhibitors to high-dose statins for secondary prevention of cardiovascular disease in Chinese adults.

Yuliang Xiang, Lei Gan,Heyue Du,Qiukui Hao,Bert Aertgeerts,Sheyu Li,Ming Hu

International journal of technology assessment in health care（2023）

引用 0|浏览8

暂无评分

摘要

In Chinese adults receiving high-dose statins for the secondary prevention of CVDs, adding ezetimibe is cost-effective compared to adding PCSK9 inhibitors and adding both drugs.

查看译文

关键词

secondary prevention, PCSK9 inhibitors, cost-effectiveness, ezetimibe, cardiovascular disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要